ASF Lok, BJ McMahon - Chrome hepatitis - maladiesinfectieuses.hug-ge.ch These guidelines have been written to assist physicians and other health care providers in the
recognition, diag- nosis, and management of patients chronically infected with the hepatitis B
virus (HBV). These recommenda- tions provide a data-supported approach to patients ... Cited by 6 - Related articles - View as HTML - All 47 versions
VWS Wong, GLH Wong, AML Chim, PCL Choi, … - Clinical Gastroenterology …, 2009 - Elsevier One hundred ninety-five patients with adequate pretreatment and post-treatment liver biopsies
(15 mm long and 6 portal tracts) were followed for 86 months (interquartile range, 77–98).
Liver-related events occurred in 12 patients (6%). The risk of liver-related events was ... Cited by 2 - Related articles - All 2 versions
G Brook, J Main, M Nelson, S Bhagani, E Wilkins, C … - bhiva.org British HIV Association guidelines for the management of coinfection with HIV-1 and chronic
hepatitis B or C 2009 ... G Brook, J Main, M Nelson, S Bhagani, E Wilkins, C Leen, M Fisher,
Y Gilleece, R Gilson, A Freedman, R Kulasegaram, K Agarwal, C Sabin, C ... Cited by 1 - Related articles - View as HTML - All 3 versions
A Resistance - medscape.com Serum HCV RNA levels during a course of therapy are highly predictive of a favorable or unfavorable
virological response. The ability to achieve complete HCV RNA suppression to undetectable
levels at 4 weeks of therapy, known as a rapid virologic response (RVR), has a positive ... Related articles
- ►omicsonline.org [PDF] S Mukherjee - Journal of Antivirals and Antiretrovirals, 2009 - dx.doi.org Liver transplantation was approved for treatment of decompensated cirrhosis in the United States
in 1983. Until the introduction of hepatitis B immunoglobulin and nucleoside/ nucleotide analogues
nearly twenty years ago, liver transplantation for hepatitis B was characterized by ...
G Sebastiani - World Journal of Gastroenterology: WJG, 2009 - pubmedcentral.nih.gov Chronic hepatitis B and C together with alcoholic and non-alcoholic fatty liver diseases represent
the major causes of progressive liver disease that can eventually evolve into cirrhosis and its
end-stage complications, including decompensation, bleeding and liver cancer. ... Related articles - All 5 versions
A Statements - medscape.com Sammy Saab, MD, MPH, AGAF Associate Professor of Medicine and Surgery; David Geffen School
of Medicine at UCLA; University of California, Los Angeles; Los Angeles, California Sammy
Saab, MD, MPH, AGAF, has disclosed that he owns stock, stock options, or bonds in ... Related articles - All 2 versions
A Edwards - Epidemiology, 2009 - Springer STIs and their associated diseases remain a major cause of morbidity and mortality
worldwide. Over the cen- turies the patterns of STI disease incidence, prevalence and virulence
have changed, and especially so over the course of the last century. In the early 20th ...
A Resistance - medscape.com Treatment strategies for chronic HBV infection have evolved greatly over the last few years owing
to an increased knowledge of the natural history of HBV, the association between HBV and
HCC, and the emergence of antiviral drug resistance in the oral nucleoside and ... Related articles
[CITATION] Introduction Potential conflict of interest: Nothing to report.
EC Doo, JH Hoofnagle, GP Rodgers - Hepatology, 2009 - Wiley Subscription Services, Inc., A … Related articles
